Cabaletta Bio, Inc.
NASDAQ:CABABiotechnology
+$0.04 today
- Market cap
- $220.03M
- Beta
- 3.23
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.57
Volume 5.46M
Average 3.33M
CABA Acquisitions (Net)
Cash paid for acquiring businesses, net of cash acquired.
Cabaletta Bio, Inc.NASDAQ: CABA
Acquisitions (Net) · Q1 FY2026 · quarter ended Mar 2026
Acquisitions (net) outflow grows to $0
Q1 FY2026 acquisitions (net) was $0, compared with $0 a year earlier. Trailing-twelve-month acquisitions (net) was $0.
Context
- Acquisitions (net) increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly acquisitions (net) holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Cash FlowText generated from reported figures; not investment advice.
Acquisitions (Net) history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Acquisitions (Net) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | -100.0% |
| FY2022 | 2022-12-31 | 24.76K | — |
| FY2021 | 2021-12-31 | 0 | — |
Acquisitions (Net) vs competitors
How CABA compares with its peers on the latest reported figures
- Peers report in different currencies, so acquisitions (net) is compared through growth and share of revenue rather than absolute size.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $274K USD | — | +146.3% | 0.7% | |
| LTM Mar 2026 | $263K USD | +100.8% | — | 848.4% | |
| LTM Mar 2026 | $70K USD | — | — | — | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| LTM Mar 2026 | $0 USD | — | — | — | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $0 USD | — | — | — |
| LTM Mar 2026 | €0 EUR | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| FY2025 | A$0 AUD | — | — | 0.0% | |
| Peer median (excluding CABA) | — | +100.8% | +146.3% | 0.0% | |
Competitors are the stored peer set for CABA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (46.29M) | (52.98M) | (67.68M) | (115.86M) | (167.86M) |
| Depreciation & Amortization | 733K | 1.18M | 1.43M | 1.71M | 1.65M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 5.8M | 6.9M | 11.34M | 19.47M | 20.94M |
| Change in Working Capital | 5.58M | (4.3M) | 101K | 1.61M | (379K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 975K | (28K) | 1.68M | 1.01M | 1.55M |
| Other Working Capital | 4.61M | (4.27M) | (1.57M) | 600K | (1.93M) |
| Other Non-Cash Items | 62K | 2.82M | 1.26M | 4.86M | 14.57M |
| Operating Cash Flow | (34.11M) | (46.38M) | (53.55M) | (88.22M) | (131.08M) |
| Capital Expenditures | (1.17M) | (2.45M) | (687K) | (2.21M) | (1.23M) |
| Acquisitions (Net) | 0 | 24.76K | 0 | 0 | 0 |
| Purchases of Investments | 0 | (49.76M) | (84.26M) | 0 | (99.04M) |
| Sales of Investments | 7.17M | 25M | 62.5M | 49.5M | 50M |
| Other Investing Activities | 0 | (24.76K) | 0 | 0 | 0 |
| Investing Cash Flow | 6M | (27.22M) | (22.45M) | 47.29M | (50.27M) |
| Debt Repayment | 0 | 0 | 0 | (897K) | (6.26M) |
| Common Stock Issued | 48.25M | 32.86M | 185.2M | 10.88M | 106.61M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 650K | 127K | 2.43M | 1.7M | 0 |
| Financing Cash Flow | 48.9M | 32.98M | 187.63M | 11.68M | 100.35M |
| Effect of Forex Changes | 0 | 0 | 0 | (20K) | 19K |
| Net Change in Cash | 20.79M | (40.62M) | 111.63M | (29.28M) | (80.98M) |
| Free Cash Flow | (35.28M) | (48.83M) | (54.24M) | (90.43M) | (132.31M) |
Cabaletta Bio, Inc.
NASDAQ:CABA
Intrinsic Alpha fair value
Locked
Current Price
$1.02
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.